关键词：多发性硬化；慢性；炎症性；导致脱髓鞘；轴突横断
摘 要：Multiple sclerosis is a chronic, inflammatory medical condition, which results in demyelination, axonal transection, and neurodegeneration of the nerve cells of the brain and spinal cord. The immune system of the body targets the neurons within the CNS and damages the myelin sheath. It is a potentially debilitating disease, causing disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with severe form of the disease can experience speech and movement problems. Multiple sclerosis can be broadly classified into four types: RRMS, SPMS,PPMS, and PRMS.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Product Profiles

04.1.1 Betaferon/Betaseron/Extavia

04.1.2 Avonex/Rebif

04.1.3 Fampyra

04.1.4 Tecfidera

04.1.5 Tysabri

04.1.6 Gilenya

04.1.7 Copaxone

05. Market Research Methodology

05.1 Market Research Process

05.2 Research Methodology

06. Introduction

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Rate of Incidence and Prevalence

08. Market Segmentation by Molecule Type

08.1 Global Biologics Market

08.1.1 Market Size and Forecast

08.2 Global Small Molecules Market

08.2.1 Market Size and Forecast

09. Market Segmentation by Route of

Administration

09.1 Global Oral Drugs Market

09.1.1 Market Size and Forecast

09.2 Global Parenteral Drugs Market

09.2.1 Market Size and Forecast

10. Geographical Segmentation

10.1 Multiple Sclerosis Drugs Market in the US

10.1.1 Market Size and Forecast

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Market Share Analysis 2013

18.2.1 Bayer

18.2.2 Biogen Idec

18.2.3 Merck Serono

18.2.4 Novartis

18.2.5 Teva Pharmaceuticals

18.3 Other Prominent Vendors

19. Key Vendor Analysis

19.1 Bayer

19.1.1 Key Facts

19.1.2 Business Overview

19.1.3 Business Segmentation

19.1.4 Business Strategy

19.1.5 Sales Segmentation by Business

19.1.6 Sales by Geographical Segmentation

19.1.7 Key Information

19.1.8 SWOT Analysis

19.2 Biogen Idec

19.2.1 Key Facts

19.2.2 Business Overview

19.2.3 Business Segmentation by Revenue 2013

19.2.4 Geographical Segmentation by Revenue 2013

19.2.5 Business Strategy

19.2.6 Key Developments

19.2.7 SWOT Analysis

19.3 Merck Serono

19.3.1 Key Facts

19.3.2 Business Overview

19.3.3 Geographical Segmentation by Revenue 2013

19.3.4 Business Strategy

19.3.5 Recent Developments

19.3.6 SWOT Analysis

19.4 Novartis

19.4.1 Key Facts

19.4.2 Business Overview

19.4.3 Business Segmentation by Revenue 2013

19.4.4 Business Segmentation by Revenue 2012 and 2013

19.4.5 Sales by Geography

19.4.6 Business Strategy

19.4.7 Key Developments

19.4.8 SWOT Analysis

19.5 Teva Pharmaceuticals

19.5.1 Key Facts

19.5.2 Business Overview

19.5.3 Business Segmentation

19.5.4 Business Segmentation by Revenue 2013

19.5.5 Business Segmentation by Revenue 2012 and 2013

19.5.6 Sales by Geography

19.5.7 Business Strategy

19.5.8 Key Developments

19.5.9 SWOT Analysis

20. Other Reports in this Series